Issuu on Google+

Lucentis (Microvascular Complications of Diabetes) Forecast and Market Analysis to 2022 Reportstack Reportstack Contact contactus@reportstack.com


Summary  The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.  Lucentis (ranibizumab) is a humanized fragment antigen-binding(Fab) fragment of an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that specifically binds to all isoforms of vascular endothelial growth factor (VEGF)-A, thereby preventing the binding of VEGF-A to its vascular endothelial growth factor receptor (VEGFR)-1 and (VEGFR-2) (Bandello et al., 2012).

Reportstack Contact contactus@reportstack.com


Scope of the report 

Overview of MCD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Lucentis including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Lucentis for the top seven countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reportstack Contact contactus@reportstack.com


Key Benefits  Understand and capitalize by identifying products that are most likely to ensure a robust return

 Stay ahead of the competition by understanding the changing competitive landscape for MCD

 Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

 Make more informed business decisions from insightful and in-depth analysis of Lucentis performance

 Obtain sales forecast for Lucentis from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Reportstack Contact contactus@reportstack.com


Companies Mentioned ď Ź

Empresa Nacional de Electricidade

Reportstack Contact contactus@reportstack.com


If you are interested... ď Ź

Contact Debora White Reportstack Market Research Email: debora@reportstack.com Ph: +1-888-789-6604

http://www.reportstack.com

Reportstack Contact contactus@reportstack.com


Lucentis (microvascular complications of diabetes) forecast and market analysis to 2022